Stock Track | WAVE Life Sciences Soars 13.39% Intraday on Positive Obesity Drug Data and Analyst Upgrades

Stock Track12-10

WAVE Life Sciences (WVE) surged 13.39% intraday on Tuesday, continuing its upward momentum following promising interim Phase 1 trial results for its investigational obesity therapy, WVE-007.

The data showed a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass at three months, with no meaningful changes in the placebo group. The drug also demonstrated sustained reductions in serum Activin E and was well-tolerated up to 600 mg doses.

Analysts reacted positively, with RBC upgrading the stock to Outperform and raising its target price to $27 from $9, Wells Fargo lifting its target to $29 from $16, and Citigroup boosting its target to $30 from $16. Cantor Fitzgerald and Clear Street maintained their bullish ratings, reflecting growing confidence in WVE-007's commercial potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148703051?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 02:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148703051","market":"nz","top_or_hot":-1,"title":"Stock Track | WAVE Life Sciences Soars 13.39% Intraday on Positive Obesity Drug Data and Analyst Upgrades","media":"Stock Track","content":"<p>WAVE Life Sciences (WVE) surged 13.39% intraday on Tuesday, continuing its upward momentum following promising interim Phase 1 trial results for its investigational obesity therapy, WVE-007.</p><p>The data showed a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass at three months, with no meaningful changes in the placebo group. The drug also demonstrated sustained reductions in serum Activin E and was well-tolerated up to 600 mg doses.</p><p>Analysts reacted positively, with RBC upgrading the stock to Outperform and raising its target price to $27 from $9, Wells Fargo lifting its target to $29 from $16, and Citigroup boosting its target to $30 from $16. Cantor Fitzgerald and Clear Street maintained their bullish ratings, reflecting growing confidence in WVE-007's commercial potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | WAVE Life Sciences Soars 13.39% Intraday on Positive Obesity Drug Data and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WAVE Life Sciences Soars 13.39% Intraday on Positive Obesity Drug Data and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-10 02:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WAVE Life Sciences (WVE) surged 13.39% intraday on Tuesday, continuing its upward momentum following promising interim Phase 1 trial results for its investigational obesity therapy, WVE-007.</p><p>The data showed a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass at three months, with no meaningful changes in the placebo group. The drug also demonstrated sustained reductions in serum Activin E and was well-tolerated up to 600 mg doses.</p><p>Analysts reacted positively, with RBC upgrading the stock to Outperform and raising its target price to $27 from $9, Wells Fargo lifting its target to $29 from $16, and Citigroup boosting its target to $30 from $16. Cantor Fitzgerald and Clear Street maintained their bullish ratings, reflecting growing confidence in WVE-007's commercial potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"","article_id":"1148703051","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148703051","pubTimestamp":1765305984,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"WAVE Life Sciences (WVE) surged 13.39% intraday on Tuesday, continuing its upward momentum following promising interim Phase 1 trial results for its investigational obesity therapy, WVE-007.The data...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"个股追踪|WAVE Life Sciences盘中大涨13.39%，因肥胖药物数据利好及分析师上调评级","themeId":"555c7582c603e30adb6ccf2ae0112896","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":1},"content_text":"WAVE Life Sciences (WVE) surged 13.39% intraday on Tuesday, continuing its upward momentum following promising interim Phase 1 trial results for its investigational obesity therapy, WVE-007.The data showed a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass at three months, with no meaningful changes in the placebo group. The drug also demonstrated sustained reductions in serum Activin E and was well-tolerated up to 600 mg doses.Analysts reacted positively, with RBC upgrading the stock to Outperform and raising its target price to $27 from $9, Wells Fargo lifting its target to $29 from $16, and Citigroup boosting its target to $30 from $16. Cantor Fitzgerald and Clear Street maintained their bullish ratings, reflecting growing confidence in WVE-007's commercial potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148703051","isCrawlerRequest":true}